2019ESC房颤管理指南-房颤患者卒中预防防治.pptVIP

The overall message is that dose adjustment of dabigatran is not a requirement for patients with mild or moderate renal impairment, but this may be required on an individual level and should be determined by the patient’s bleeding risk. For other NOACs, dose adjustment is indicated based on renal function.1–4 The dose of apixaban should be reduced from 5 mg to 2.5 mg BID in patients with any two of the following: serum Cr ≥1.5 mg/dL, age ≥80 years or body weight ≤60 kg. Rivaroxaban dose should be reduced from 20 mg to 15 mg in patients with moderate renal impairment. Due to increased plasma